Archive for the ‘Medical Reviews’ Category
Could there be a better way to eliminate skin cancer without scarring the face? Could there be a medical breakthrough in the treatment of skin cancer? The answer is YES , there is, and it is a skin cream called Cura-Derm or BEC-5 discovered in 1979 and developed by a biochemist in Australia named Bill Cham, PhD.
Dr. Cham’s friend was a veterinarian and he noticed that one of his sick cows recovered from cancer in the eye after rubbing the eye on a Devil’s Apple plant. This piqued his interest so he isolated the active ingredient in the plant which had anti-cancer activity. Eventually, this was made into a skin cream and extensively tested for safety and efficacy.
The cream works exceedingly well with non-melanoma skin cancers such as squamous cell and basal cell which are the common varieties. One advantage is that the cancer “melts away” leaving normal skin with no scarring . Skin cancer involving the lip is an excellent case for the cream since surgery can be disfiguring, while the BEC5 skin cream allows a smoothly healed result.
On average a 20ml bottle of the skin cream can manage one to two large non-melanoma skin cancers, two to three medium sized ones or perhaps twelve sun spots. The bottle costs about 120 dollars. Please note that I have no financial connection with Curaderm or Dr. Cham, and our office does not carry it. However, it is widely available from Dr. Cham and other resellers on the Internet. Should you wish to try this product, please use it in consultation with your dematologist, of course.
(2) Photo Album of Skin Cancer Cases Before and After Treatment on the Curaderm Blog
(6) Bec5: The Treatment Of Choice,
For Non-Melanoma Skin Cancers By Bill E. Cham, Ph.D.
(7) Interview with Bill Cham
(9) Cancer Letter 1991 Sep;59(3):183-92. Topical treatment of malignant and premalignant skin lesions by very low concentrations of a standard mixture (BEC) of solasodine glycosides. Cham BE, Daunter B, Evans RA. Department of Medicine, University of Queensland, Australia.
A cream formulation containing high concentrations (10%) of a standard mixture of solasodine glycosides (BEC) has been shown to be effective in the treatment of malignant and benign human skin tumours. We now report that a preparation (Curaderm) which contains very low concentrations of BEC (0.005%) is effective in the treatment of keratoses, basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs) of the skin of humans. In an open study, clinical and histological observations indicated that all lesions (56 keratoses, 39 BCCs and 29 SCCs) treated with Curaderm had regressed. A placebo formulation had no effect on a smaller number of treated lesions. Curaderm had no adverse effect on the liver, kidneys or haematopoietic system.
(9) Cancer Letter 1987 Aug;36(2):111-8.
Glycoalkaloids from Solanum sodomaeum are effective in the treatment of skin cancers in man. by Cham BE, Meares HM.
A cream formulation containing glycoalkaloids purified from the plant species Solanum sodomaeum L. is effective in the treatment of the malignant human skin tumours; basal cell carcinomas (BCCs), squamous cell carcinomas (SCCs) and the benign tumours; keratoses and keratoacanthomas. Histological analyses of biopsies taken before, during and after treatment give compelling evidence of the efficacy of the formulation. The treated lesions did not recur for at least 3 years after cessation of therapy. The observed complete regressions were; 20/24 for the BCCs; 5/6 for the SCCs; 23/23 for the keratoses; and, 9/9 for the keratoacanthomas. Biochemical, haematological and urinanalytical studies demonstrated that there were no adverse effects on the liver, kidneys or haematopoietic system during treatment. Normal skin treated with the formulation likewise was free from adverse histological or clinical effects. The data indicate that glycoalkaloids of this type are therefore potentially useful in the treatment of several types of human skin cancers.
(11) Cancer Letter 1990 Dec 17;55(3):221-5.
Solasodine glycosides. Selective cytotoxicity for cancer cells and inhibition of cytotoxicity by rhamnose in mice with sarcoma 180. Cham BE, Daunter B. University of Queensland, Department of Medicine, Australia.
BEC, a standard mixture of solasodine glycosides is effective in vivo against murine sarcoma 180 (S180), whereas the aglycone solasodine at equimolar concentrations is ineffective. The efficacy of BEC against S180 in vivo can be inhibited by rhamnose. Mice which are in their terminal stage with S180 can tolerate and become symptom-free of cancer by single dose administration of BEC at concentrations of BEC three times the LD100 for normal mice. These observations suggest that the binding of solasodine glycosides on tumour cells may be mediated through the monosaccharide rhamnose, which forms part of solasonine, solamargine and di-glycosides of solasodine in BEC. Furthermore, these results provide evidence that BEC selectively destroys tumour cells relative to normal cells in vivo.
(12) Cancer Letter 1990 Dec 17;55(3):209-20.
Solasodine glycosides. In vitro preferential cytotoxicity for human cancer cells.
Daunter B, Cham BE. University of Queensland Department of Obstetrics and Gynaecology, Herston, Australia. Solamargine [(22R,25R)-spiro-5-en-3 beta-yl-alpha-L-rhamnopyranosyl- (1----2glu)-O-alpha-L-rhamnopyranozyl (1----4glu)-beta-D-glucopyranoze], a glycoside of solasodine preferentially inhibits the uptake of tritiated thymidine by cancer cells. In contrast, solamargine at equivalent concentration, and the mono- and diglycosides of solasodine have a limited effect on the uptake of tritiated thymidine for other cell types, including unstimulated lymphocytes and lymphocytes stimulated with Con A. In contrast the solasodine glycosides do not inhibit the uptake of tritiated thymidine by lymphocytes stimulated with PHA or PWM. The inhibition of tritiated thymidine uptake by solamargine and the mono- and di-glycosides of solasodine are dependent upon their cellular uptake by endogenous endocytic lectins (EELs). The mode of action of the solasodine glycosides, in particular solamargine, appears to be the induction of cell lysis, as determined by morphological examination.
Eggplant news, articles and information
(NaturalNews) An ingredient in common eggplant has been shown to cure cancer. The eggplant extract is a phytochemical called solasodine glycoside, or BEC5. Dr. Bill E. Cham discovered it, after hearing of a folk medicine cure from Australian farmers. They told him of eye cancers cured in cattle after application of a poultice made from the fruit of a weed called Devil”s Apple, known in Latin as Solanum linnaeanum. This plant is part of the Solanacea family, which includes other common vegetables such as tomato and eggplant.
Actinic keratoses are a possible predictor of skin cancer. These red patches caused by sun exposure are made of abnormal cells that can mutate intomalignant cells in the basal, or lower layers of the skin. Squamous cell carcinomas are another common form of skin cancer and one which causes nearly two thousands deaths annually. This wart-type growth has irregular borders and can also be treated with the eggplant extract.
Used as a cream for over twenty-five years in clinical trials in both Australia and the United Kingdom, BEC5 had success rate of over 78% when applied for eight weeks. Used for 12 weeks, the cream had a 100% success rate in removing cancers, none of which returned for the following five years.
Over one million new cases of non-melanoma skin cancers are diagnosed each year in the United States alone. Skin cancer is now the most common illness in men over the age of 50. It is even more common than lung, prostate or colon cancer. Incidences are so common that one out of three Caucasians are now expected to develop skin cancer at some point in their lives. With this simple, natural remedy, many surgeries might be prevented and health restored.
A NaturalNews.com event features two courageous and outspoken holistic medical professionals who are putting their careers on the line to bring you the uncensored truth about natural approaches to cancer: Dr Richard Linchitz, M.D.and Dr Nicholas Gonzalez, M.D.
Together, they are gearing up to deliver an interactive, solutions-oriented LIVE webcast of natural cancer cures, proven remedies and scientific data on what”s working right now to help people heal themselves of cancer.
However, there are inexpensive, effective, safe cures for curing skin cancer that are banned by the mainstream medical monopoly, which are not publicized by the mainstream media.
Also featured on Naturalnews.com is information on Curaderm-BEC5 for Skin Cancer;
A relatively new remedy, BEC5, is a spin off from an Australian folk remedy for farm animals. It is available to anyone online. It uses the phyotonutrients extracted from eggplants. Clinical trials and anecdotal testimonies confirmed BEC5″s efficacy and safety on basal cell and squamous cell cancers.
New Specific Treatments
Over 7,000 of the commonly prescribed drugs in the western world are derived from plants. Indeed, the plant kingdom has supplied us with some excellent drugs. Pain sufferers appreciate the relief provided by morphine. Victims of congestive heart failure appreciate the life-saving role of digitoxin or digoxin. Migraine patients experience the dramatic relief effected by ergotamine. Children with leukaemia have recognized the improvement of their condition by treatment with vincristine.
It is now well established that specific glycoalkaloids from the Solanum family have anticancer properties. The specific glycoalkaloids consist of BEC, which is a standardised mixture of triglycosides, solasonine and solamargine and their corresponding di- and mono-glycosides (1-12). All the glycosides contain the same aglycone, (the alkaloid without a sugar molecule)- solasodine.
Solasodine on its own does not have anticancer properties, however the mono-, di- and triglycosides do have anticancer properties. These glycosides contain a plant sugar rhamnose, which is not usually found in mammalian species. Specific endogenous lectins (EELS), which are specific receptors for the sugar part of the glycoalkaloids and are present in the plasma membranes of susceptible cancer cells but not normal cells recognize and bind the sugar rhamnose of the BEC glycoalkaloids. BEC subsequently enters the cancer cell and causes cell death by destroying the lysosome (6, 13-17).
BEC has been shown to have antineoplastic activity in cell culture, animals and in humans (1, 3-12). Currently Phase II studies with BEC are being carried out on terminal internal tumours in man. With these studies BEC in being administered intravenously (18).
It is important to note that Curaderm-BEC5 contained extremely low concentrations of BEC (0.005%). One tube of Curaderm containing 20g of cream formulation contained the equivalent of BEC as 5g of eggplant fruit (19). However, for BEC to be effective it must first be purified from its source by a specific process. Unlike other extracts used for therapeutic effects, in which the active ingredients have to be concentrated, with Curaderm-BEC5 the active ingredients in the plant material have to be diluted to still obtain the anticancer effects. In other words, the active glycoalkaloid ingredients are extremely safe as Curaderm-BEC5 contains less glycoalkaloid than the edible eggplant fruit!
Curaderm-BEC5 is applied at least twice daily to the skin and may be applied much more frequently if rapid regression of the tumour is required. Some patients apply the Curaderm-BEC5 cream up to 10 times daily. The cosmetic results after using Curaderm BEC5 are very impressive and over 80,000 patients have now used Curaderm-BEC5 successfully.
British clinical trials with Curaderm-BEC5
Recently a double-blind, vehicle-controlled (placebo), randomised, parallel group study of 94 patients was carried out to assess the efficacy and safety of Curaderm-BEC5 in the treatment of patients with BCC. This was a multi-centre Phase III study involving 10 centres in the United Kingdom.
The centres were as follows:
- University of Wales College of Medicine.
- Leicester Royal Infirmary.
- The Royal London Hospital.
- St. Mary’s Hospital.
- St. Thomas’ Hospital.
- Royal Free Hospital.
- Singleton Hospital.
- Royal Liverpool Hospital.
- Derriford Hospital.
- Hope Hospital.
The objectives of the study were to evaluate the efficacy and safety of Curaderm-BEC5 in the treatment of BCCs. The primary endpoint was defined as the complete healing of the index lesions, as confirmed by the absence of tumour- determined by clinical and histological examination after 8 weeks of twice daily treatments with Curaderm-BEC5 or placebo. The secondary endpoints were cosmetic evaluation, physician’s global evaluation of response to treatment, assessment of local irritation, reduction in size of the lesion and assessment of the frequency, nature and severity of adverse events.
The success rate (complete remission of skin cancers) of the Curaderm-BEC5 cream was 78% within 8-weeks. Longer than the 8 weeks duration therapy with Curaderm-BEC would have resulted in even higher success rates. These results were comparable to those previously obtained and published (4, 5, 13, 14). Not only was it shown that Curaderm-BEC5 was effective in treating superficial BCC, but in a subsequent open study trial comprising 41 patients (carried out at the Dermatology Department at the Royal London Hospital), it was also shown that Curaderm-BEC5 was effective on morpheoic BCC lesions, which are a type of invasive BCC.
The clinical trial experience has shown that Curaderm-BEC5 is safe. Only local skin irritation, some pain and erythema (reddening) occurred during treatment. Success was defined as zero presence of BCC after histological (microscopic) examination of samples, removed from the lesion sites by punch biopsy.
The conclusion of the dermatologists at the Royal London Hospital is that; “Curaderm-BEC5 is a topical preparation, which is safe and effective and an ideal therapy for outpatient treatment.” They stated further that; “Curaderm-BEC5 is a much-needed alternative to surgery for BCC. This is the most common cancer in Caucasians worldwide and the prevalence continues to increase with an increasing ageing population.” The final conclusion of these investigations was that; “Curaderm-BEC5 is a cost effective treatment for both primary and secondary skin cancer care.”
These Phase III and open studies confirm the previously published articles that; Curaderm-BEC5 is the method of choice for treating non-melanoma skin cancers.
United Kingdom Hospitals Dermatologist Clinical Trial
Dermatology Department 2nd Floor Outpatient Building
Hospital White Chapel London, E1 1BB
Tuesday April 23rd 2002
CLINICAL APPRAISAL of BEC5
You have requested us to detail our clinical experience with BEC5 in the treatment of malignant lesions of the skin. We understand that this may be shown to potential purchasers of BEC5.
The Dermatology Department at the Royal London Hospital has acted as an approved and designated center in two clinical trials to determine the safety and efficacy of BEC 5 cream in the treatment of cancerous lesions of the skin. In the first of these, a pivotal double blind randomized study; Royal London recruited, treated and monitored 21 of the 94 patients. In the second trial, comprising 41 patients, Royal London was the sole designated centre. This trial was an open study, conducted primarily assess the safety of the product. Herewith we summarize our observation on the use, safety, efficacy, cosmetic result and resource effectiveness of the product.
The trials were formally restricted to patients diagnosed by physician as having superficial basal cell carcinoma. Hence patients with morpheoic lesions were excluded. However subsequently conducted punch biopsy results demonstrated that several trial patients did in deed have basal cell carcinoma. Even so our findings in respect of these patients were that successful treatment of the invasive form of basal cell carcinoma paralleled the general success rate of BEC5 ie, around 78%.
In our view these results, in the least justify a more extensive clinical trial of BEC5 against such cancers. We note in this respect that treatment of the morpheoic form of the affliction is presently confined to surgical removal. We are not aware of any emerging therapy, for example, photodynamic therapy that has the potential to extend to treatment of other than superficial skin cancers.
Our clinical experience has shown that BEC5 is safe. In the two frequent (twice daily) and prolonged (8 weeks) application of a cream incorporating BEC5 under occlusive dressing resulted only in local skin irritation and erythema. Very few patients under our supervision withdrew from treatment on this account. Hence we consider treatment with BEC5 to be safe therapy.
Furthermore, patient blood and urine was analyzed using very sensitive methods to determine the presence of the BEC5 during and after a standard treatment regime (twice daily for 8 weeks). Such analysis produced no evidence of the active pharmaceutical ingredients to BEC5 or their breakdown products. Hence, it was concluded that there is no systemic absorption of BEC5. This is extremely important from the clinical perspective and may be contrasted with other topical preparations. For example, 5 fluouracil shows systemic absorption and can prove to be toxic when used with large lesions.
Royal London has a large dedicated skin cancer clinic as it is a Skin Cancer Center for the North East Thames Network. This fact, coupled with the results of the first trial, was instrumental on Royal London”s conduct of second open study. Success rates in this open trial paralleled the multi-center efficacy rate of 78%. Success was defined as zero presence of basal cell carcinoma after histological examination of samples extracted from the lesion site by punch biopsy.
We consider that this rate of treatment success more than justifies the physician considering BEC5 as an alternative to currently predominant treatment such as surgical excision or cryotherapy.
BEC results in ulceration of the lesion site during treatment. However, we have observed that post treatment the wound is quickly replenished with normal tissue and that residual scarring is minimal. Whether such scarring proves more or less extensive than that consequent upon surgical excision is dependant on a number of factors including lesion size, location and so on. However, it can be said that the cosmetic results offered by treatment with BEC5 are comparable to that resulting from surgical excision.
Basal Cell Carcinoma is a slow growing locally invasive malignant skin tumor which mainly affects Caucasians. Dermatologists, plastic surgeons and radiotherapists jointly manage the affliction, such management usually involves surgery. The risks of surgical intervention are well known.
Moreover, excision of basal cell carcinoma from the facial area often involves reconstructive, which can be both time consuming and costly. Hence an alternative, safe and efficacious method of treatment of basal cell carcinoma that does not require physician or hospital attendance must be encouraged.
In our view and experience BEC5 is a topical preparation, which is safe and effective, ideal therapy for outpatient treatment. Hence BEC5 is a much needed alternative to surgery for basal cell carcinoma. This is the commonest cancer in Caucasians worldwide and the prevalence continues to increase with an increasing ageing population. It is a cost effective treatment for both primary and secondary skin cancer care.
We trust that the following is adequate for your purposes
Rino Cerio BS (Lond) FRCP (Edin) FRCPath Consultant Dermatologist and Senior Lecturer in Dermatopathology
Dr. Sangeeta Punjabi MBBS, DVD, DipNB (Dermatology) Research Registrar, Royal London Hospital
NOTE: This is a transcript of the clinical evaluation of by
Barts And The London NHS – NHS Trust